
Spoločnosť UniQure oznamuje, že FDA udelila AMT-130 označenie prelomovej terapie na liečbu Huntingtonovej choroby
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application